COHERUS ONCOLOGY INC
CHRSNASDAQ🏆 #3428 by market capEarnings Nov 5US Equity
$1.20▼ $0.01 (−1.24%)
Live1h▼ 2.4%
24h▼ 1.2%
7d▼ 17.6%
14d▼ 15.2%
30d▼ 19.3%
1y▲ 30.7%
🏦Market Cap
$185M
Small Cap
📈Revenue Growth (YoY)
-84.2%
Declining
📊Gross Margin
63.5%
High
💵FCF Margin
-478.9%
Thin
⚖️P/S Ratio
3.7x
Fair
Otter Score
51
Weak
📊
Analyst Ratings
Price
$1.20
Total
16
Raised
1
Lowered
0
Avg PT
$6.02
H / L
$11 / $1
| Institution | Action | Rating | Date |
|---|---|---|---|
Maxim Group | Upgraded | Hold → Buy | 2025-09-04 |
HC Wainwright & Co. | Reiterated | Buy | 2025-04-29 |
UBS | Reiterated | Neutral | 2025-04-24 |
Baird | Reiterated | Outperform | 2024-12-05 |
Truist Securities | Reiterated | Buy | 2024-05-13 |
Barclays | Reiterated | Overweight | 2023-10-23 |
Mizuho | Reiterated | Buy | 2022-11-16 |
JP Morgan | Reiterated | Neutral | 2022-11-14 |
B of A Securities | Reiterated | Neutral | 2020-07-16 |
SunTrust Robinson Humphrey | Reiterated | Buy | 2020-04-17 |
H.C. Wainwright | Reiterated | Buy | 2020-02-28 |
Citigroup | Reiterated | Buy | 2019-11-07 |
BMO Capital | Reiterated | Outperform | 2017-05-05 |
Standpoint Research | Reiterated | Speculative Buy → Buy | 2016-11-25 |
Credit Suisse | Reiterated | Outperform | 2016-01-20 |
Cowen & Co. | Reiterated | Outperform | 2014-12-01 |
One row per institution, most recent rating